However, only a fraction of these will ever make it to the market due to the economic and inherent scientific challenges in the drug development process.
14122
这加上成功的抗生素产品带来的投资回报很小，限制了主要私人投资者和大多数大型制药公司的兴趣。
This, along with the small return on investment from successful antibiotic products, has limited the interest of major private investors and most large pharmaceutical companies.
14123
报告证实，临床前和临床开发继续由中小型企业驱动。
The report confirms that the preclinical and clinical pipeline continue to be driven by small- and medium-sized companies.
14124
这些企业通常很难为其产品筹资直到临床开发后期阶段，或者直到获得监管机构的批准。
These enterprises often struggle to finance their products to the late stages of clinical development or until regulatory approval is obtained.
14125
2019冠状病毒病（COVID-19）带来的机遇
The COVID-19opportunity:
14126
COVID-19危机加深了全球对这场不可控制的大流行对健康和经济的影响的理解。
The COVID-19 crisis has deepened the global understanding of the health and economic implications of an uncontrolled pandemic.
It also accentuated the gaps in sustainable funding to address these risks, including investments in R&D of antimicrobial medicines and vaccines, whilst revealing what rapid progress can be made when there is enough political will and enterprise.
“Opportunities emerging from the COVID-19 pandemic must be seized to bring to the forefront the needs for sustainable investments in R&D of new and effective antibiotics,” said Haileyesus Getahun, Director of AMR Global Coordination at WHO.
14129
我们需要全球持续努力，包括资金统筹机制和新的额外投资，以应对抗微生物药物耐药性的规模。”
“Antibiotics present the Achilles heel for universal health coverage and our global health security.